Literature DB >> 18165760

Alemtuzumab.

Timothy A Weaver1, Allan D Kirk.   

Abstract

Alemtuzumab is a humanized CD52-specific monoclonal antibody that is increasingly used off-label as an induction agent in solid organ transplantation, particularly in the setting of maintenance immunosuppression minimization protocols. In this review, we briefly discuss this agent's mechanisms of action and summarize evidence supporting its use in this clinical setting.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18165760     DOI： 10.1097/01.tp.0000296680.75175.67

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Pancreatic islet transplantation: toward definitive treatment for diabetes mellitus.

Authors:  Tadashi Takaki; Masayuki Shimoda
Journal:  Glob Health Med       Date:  2020-08-31

Review 2.  Induction and maintenance immunosuppression in lung transplantation.

Authors:  Bronwyn Small; Jenny Au; Heidi Brink; Ishani Shah; Heather Strah
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-09-17

3.  Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes.

Authors:  Tatiana Froud; David A Baidal; Raquel Faradji; Pablo Cure; Davide Mineo; Gennaro Selvaggi; Norma S Kenyon; Camillo Ricordi; Rodolfo Alejandro
Journal:  Transplantation       Date:  2008-12-27       Impact factor: 4.939

4.  Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis.

Authors:  Mingjie Shao; Tingting Tian; Xinyan Zhu; Yingzi Ming; Yasuko Iwakiri; Shaojun Ye; Qifa Ye
Journal:  Oncotarget       Date:  2017-08-02

5.  Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.

Authors:  A C Dietz; P J Orchard; K S Baker; R H Giller; S A Savage; B P Alter; J Tolar
Journal:  Bone Marrow Transplant       Date:  2010-04-12       Impact factor: 5.174

6.  Lymphocyte modulation with FTY720 improves hemorrhagic shock survival in swine.

Authors:  Jason S Hawksworth; J Christopher Graybill; Trevor S Brown; Shannon M Wallace; Thomas A Davis; Doug K Tadaki; Eric A Elster
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

7.  The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

Authors:  Phuong-Thu T Pham; Gerald S Lipshutz; Phuong-Truc T Pham; Joseph Kawahji; Jennifer S Singer; Phuong-Chi T Pham
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

8.  Th17 mediated alloreactivity is facilitated by the pre-transplant microbial burden of the recipient.

Authors:  Aleksandra Klimczak; Andrzej Lange
Journal:  Bone Marrow Res       Date:  2012-10-09

9.  Lymphocyte depletion in experimental hemorrhagic shock in Swine.

Authors:  Jason S Hawksworth; Christopher Graybill; Trevor S Brown; Suzanne M Gillern; Shannon M Wallace; Thomas A Davis; Eric A Elster; Doug K Tadaki
Journal:  J Inflamm (Lond)       Date:  2012-09-25       Impact factor: 4.981

Review 10.  Monoclonal antibody therapy and renal transplantation: focus on adverse effects.

Authors:  Gianluigi Zaza; Paola Tomei; Simona Granata; Luigino Boschiero; Antonio Lupo
Journal:  Toxins (Basel)       Date:  2014-02-28       Impact factor: 4.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.